Uses: The uses of Reminyl ( Galantamine ) include: Reminyl is the brand name for the drug galantamine hydrobromide. It is licensed for the treatment of mild to moderately severe Alzheimer's disease. Reminyl is not claimed to be a cure for Alzheimer's disease. It treats only the symptoms and there is no evidence to show that it could halt or reverse the process of cell damage that causes Alzheimer's disease. Who might benefit? Reminyl is intended only for people with Alzheimer's disease, and not for people with other kinds of dementia. It is licensed only for people who are in the mild to moderately severe stages of the illness. It is important to realise that unfortunately Reminyl will not help everyone who tries it. Effects - The effect of the drug will vary for different people. Some will not notice an effect at all. Others may find that their condition improves, or that they stay the same when they would have expected to get gradually less able because of the progression of Alzheimer's disease. For most who take it there will not be a dramatic improvement, but the drug may help to stop symptoms getting worse. Janssen-Cilag and Shire, who manufacture the drug, did studies looking at the drug’s effect on memory and understanding, behaviour and people’s ability to carry out daily living activities. The results of the studies are averages, so some people did better and some worse than the average. It is not possible to tell whether the drug will have an effect for any particular person. On one measure of understanding and memory, people with Alzheimer's disease without treatment normally score 5-11 points worse after a year. After a year on the high dose of Reminyl, the average score of people taking Reminyl had stayed the same, and about a third had improved by 4 points. However, it must be remembered that 15% of people taking the placebo (dummy pill) also improved by the same amount. (This is a common effect in clinical trials when people take a placebo.) For those who took Reminyl, behavioural symptoms such as anxiety, hallucinations and wandering on average did not get worse over the course of a five month study. For some people these symptoms improved, while for those not taking the drug they got significantly worse. For activities of daily living, on average, people taking Reminyl also remained the same over a year, whereas those not taking the drug got worse at activities like bathing, managing money and preparing food.

JANSSEN CILAG manufactures Reminyl ( Galantamine ).

[Reminyl ( Galantamine )]. Medications should only be taken in accordance with the advice of your medical professional.

Buy Drugs Online Without Prescription - Click Here!

More about Reminyl ( Galantamine ) :

8mg 28 Tablets

JANSSEN CILAG manufactures Reminyl ( Galantamine ).

Uses: The uses of Reminyl ( Galantamine ) include: Reminyl is the brand name for the drug galantamine hydrobromide. It is licensed for the treatment of mild to moderately severe Alzheimer's disease. Reminyl is not claimed to be a cure for Alzheimer's disease. It treats only the symptoms and there is no evidence to show that it could halt or reverse the process of cell damage that causes Alzheimer's disease. Who might benefit? Reminyl is intended only for people with Alzheimer's disease, and not for people with other kinds of dementia. It is licensed only for people who are in the mild to moderately severe stages of the illness. It is important to realise that unfortunately Reminyl will not help everyone who tries it. Effects - The effect of the drug will vary for different people. Some will not notice an effect at all. Others may find that their condition improves, or that they stay the same when they would have expected to get gradually less able because of the progression of Alzheimer's disease. For most who take it there will not be a dramatic improvement, but the drug may help to stop symptoms getting worse. Janssen-Cilag and Shire, who manufacture the drug, did studies looking at the drug’s effect on memory and understanding, behaviour and people’s ability to carry out daily living activities. The results of the studies are averages, so some people did better and some worse than the average. It is not possible to tell whether the drug will have an effect for any particular person. On one measure of understanding and memory, people with Alzheimer's disease without treatment normally score 5-11 points worse after a year. After a year on the high dose of Reminyl, the average score of people taking Reminyl had stayed the same, and about a third had improved by 4 points. However, it must be remembered that 15% of people taking the placebo (dummy pill) also improved by the same amount. (This is a common effect in clinical trials when people take a placebo.) For those who took Reminyl, behavioural symptoms such as anxiety, hallucinations and wandering on average did not get worse over the course of a five month study. For some people these symptoms improved, while for those not taking the drug they got significantly worse. For activities of daily living, on average, people taking Reminyl also remained the same over a year, whereas those not taking the drug got worse at activities like bathing, managing money and preparing food.

For years, Americans living near Canada and Mexico have taken advantage of the low cost No Prescription Required available across the border, allowing them to purchase brand name and generic medicines like Reminyl ( Galantamine ) at substantial savings compare to prices in the United States. You must only take medications in accordance with the advice of your doctor or medical professional and you must only take No Prescription Required if you are in possession of a valid prescription.

[Reminyl ( Galantamine )]

coloradoreview.com makes no endorsements, representations or warranties regarding any services or products offered at any online pharmacies.

< Previous  Next >

Drugs Online No Prescription Required - Buy discount no prescription required drugs online and purchase your pharmacy medications today!

In what can be termed as a rude wake-up call for millions of patients taking medication, five out of six approved prescription drugs seldom benefit them, claims a new study. According to experts, despite stringent reforms to shield the public from harmful drugs, the harm-benefit ratio is worsening due to relaxed rules that allow companies to promote drugs for unapproved uses. It’s really a two-tier market for lemons.” Systematic review conducted. Light carried out systematic reviews based on a wide range of data from independent sources and studies. The findings indicate that only one in six new drugs is superior to existing drugs. Most of the new drugs result in side effects serious enough to warrant action by the health regulators, including black box warnings, adverse reaction warnings, or even withdrawal of the drug. Citing the example of chloresterol-lowering statins, Light stated that drugs companies had reduced the link between heart disease, saturated fats and cholesterol into a simple refrain that "cholesterol kills". However, two clinical trials of statins were unable to establish that they cut the risk of heart attacks. One major meta-analysis of a number of studies, found that "statins were not associated with reduction in the risk of all-cause mortality.” Clinical trials flawed - Light accuses pharmaceutical companies of designing flawed clinical trials that minimize evidence of toxic side effects. Many a times the companies test the new drugs on a healthier population atypical of patients who will actually take the drug, excluding people who are older, poorer or who have multiple health problems. Trials are run just long enough to highlight the main benefits but not long enough to detect some long term side effects. Approvals are based on these data, drugs with harmful effects sometimes get through. Light stated, "The result is that drugs get approved without anyone being able to know how effective they really are or how much serious harm they will cause." The findings of the study were presented on Aug. 17 at the 105th Annual Meeting of the American Sociological Association in Atlanta.